American Century Companies Inc. Has $99.24 Million Holdings in Alkermes plc (NASDAQ:ALKS)

American Century Companies Inc. lifted its position in Alkermes plc (NASDAQ:ALKS) by 6.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,450,707 shares of the company’s stock after purchasing an additional 209,740 shares during the quarter. American Century Companies Inc. owned 2.13% of Alkermes worth $99,242,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Natixis Advisors LLC raised its position in Alkermes by 190.3% in the third quarter. Natixis Advisors LLC now owns 36,490 shares of the company’s stock worth $1,021,000 after purchasing an additional 23,921 shares in the last quarter. Pathstone Holdings LLC raised its holdings in shares of Alkermes by 72.8% in the 3rd quarter. Pathstone Holdings LLC now owns 71,324 shares of the company’s stock worth $1,996,000 after buying an additional 30,048 shares in the last quarter. Advisors Asset Management Inc. raised its holdings in shares of Alkermes by 21.1% in the 3rd quarter. Advisors Asset Management Inc. now owns 10,158 shares of the company’s stock worth $284,000 after buying an additional 1,771 shares in the last quarter. Moors & Cabot Inc. bought a new position in shares of Alkermes during the 3rd quarter worth approximately $223,000. Finally, Intech Investment Management LLC acquired a new stake in Alkermes in the 3rd quarter valued at $1,463,000. 95.21% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have issued reports on ALKS shares. The Goldman Sachs Group increased their price objective on Alkermes from $30.00 to $32.00 and gave the stock a “buy” rating in a research note on Friday, February 14th. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Alkermes in a research report on Tuesday, February 11th. They set a “buy” rating and a $40.00 target price for the company. StockNews.com upgraded shares of Alkermes from a “buy” rating to a “strong-buy” rating in a research report on Thursday, February 13th. UBS Group raised shares of Alkermes from a “sell” rating to a “neutral” rating and raised their price objective for the stock from $21.00 to $38.00 in a report on Tuesday, March 4th. Finally, HC Wainwright reissued a “neutral” rating and issued a $46.00 target price on shares of Alkermes in a report on Thursday, February 13th. Four equities research analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $38.46.

Insider Activity at Alkermes

In related news, EVP Craig C. Hopkinson sold 144,419 shares of the company’s stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $35.53, for a total value of $5,131,207.07. Following the completion of the sale, the executive vice president now owns 57,875 shares in the company, valued at approximately $2,056,298.75. This represents a 71.39 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 4.89% of the stock is currently owned by company insiders.

Alkermes Stock Up 0.5 %

ALKS stock opened at $34.79 on Tuesday. Alkermes plc has a twelve month low of $22.90 and a twelve month high of $36.45. The company has a market cap of $5.66 billion, a P/E ratio of 16.03, a PEG ratio of 2.20 and a beta of 0.62. The business has a fifty day moving average of $33.10 and a 200-day moving average of $30.12.

Alkermes (NASDAQ:ALKS) last announced its quarterly earnings data on Wednesday, February 12th. The company reported $0.92 earnings per share for the quarter, topping the consensus estimate of $0.81 by $0.11. Alkermes had a return on equity of 30.80% and a net margin of 23.57%. As a group, equities research analysts anticipate that Alkermes plc will post 1.31 earnings per share for the current fiscal year.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.